Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

48 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer.
Bardia A, Hurvitz SA, Tolaney SM, Loirat D, Punie K, Oliveira M, Brufsky A, Sardesai SD, Kalinsky K, Zelnak AB, Weaver R, Traina T, Dalenc F, Aftimos P, Lynce F, Diab S, Cortés J, O'Shaughnessy J, Diéras V, Ferrario C, Schmid P, Carey LA, Gianni L, Piccart MJ, Loibl S, Goldenberg DM, Hong Q, Olivo MS, Itri LM, Rugo HS; ASCENT Clinical Trial Investigators. Bardia A, et al. Among authors: sardesai sd. N Engl J Med. 2021 Apr 22;384(16):1529-1541. doi: 10.1056/NEJMoa2028485. N Engl J Med. 2021. PMID: 33882206 Clinical Trial.
A phase I study of an oral selective gamma secretase (GS) inhibitor RO4929097 in combination with neoadjuvant paclitaxel and carboplatin in triple negative breast cancer.
Sardesai S, Badawi M, Mrozek E, Morgan E, Phelps M, Stephens J, Wei L, Kassem M, Ling Y, Lustberg M, Stover D, Williams N, Layman R, Reinbolt R, VanDeusen J, Cherian M, Grever M, Carson W, Ramaswamy B, Wesolowski R. Sardesai S, et al. Invest New Drugs. 2020 Oct;38(5):1400-1410. doi: 10.1007/s10637-020-00895-5. Epub 2020 Jan 17. Invest New Drugs. 2020. PMID: 31953695 Free PMC article. Clinical Trial.
Genomic features of rapid versus late relapse in triple negative breast cancer.
Zhang Y, Asad S, Weber Z, Tallman D, Nock W, Wyse M, Bey JF, Dean KL, Adams EJ, Stockard S, Singh J, Winer EP, Lin NU, Jiang YZ, Ma D, Wang P, Shi L, Huang W, Shao ZM, Cherian M, Lustberg MB, Ramaswamy B, Sardesai S, VanDeusen J, Williams N, Wesolowski R, Obeng-Gyasi S, Sizemore GM, Sizemore ST, Verschraegen C, Stover DG. Zhang Y, et al. BMC Cancer. 2021 May 18;21(1):568. doi: 10.1186/s12885-021-08320-7. BMC Cancer. 2021. PMID: 34006255 Free PMC article.
Inhibiting Fatty Acid Synthase with Omeprazole to Improve Efficacy of Neoadjuvant Chemotherapy in Patients with Operable TNBC.
Sardesai SD, Thomas A, Gallagher C, Lynce F, Ottaviano YL, Ballinger TJ, Schneider BP, Storniolo AM, Bauchle A, Althouse SK, Perkins SM, Masters AR, Stratford RE Jr, Dong Z, Liu JY, Zhang JT, Miller KD. Sardesai SD, et al. Clin Cancer Res. 2021 Nov 1;27(21):5810-5817. doi: 10.1158/1078-0432.CCR-21-0493. Epub 2021 Aug 16. Clin Cancer Res. 2021. PMID: 34400413 Clinical Trial.
Phase Ib study of HSP90 inhibitor, onalespib (AT13387), in combination with paclitaxel in patients with advanced triple-negative breast cancer.
Williams NO, Quiroga D, Johnson C, Brufsky A, Chambers M, Bhattacharya S, Patterson M, Sardesai SD, Stover D, Lustberg M, Noonan AM, Cherian M, Bystry DM, Hill KL, Chen M, Phelps MA, Grever M, Stephens JA, Ramaswamy B, Carson WE 3rd, Wesolowski R. Williams NO, et al. Among authors: sardesai sd. Ther Adv Med Oncol. 2023 Dec 25;15:17588359231217976. doi: 10.1177/17588359231217976. eCollection 2023. Ther Adv Med Oncol. 2023. PMID: 38152697 Free PMC article.
Assessment of outcomes and novel immune biomarkers in metaplastic breast cancer: a single institution retrospective study.
Morgan E, Suresh A, Ganju A, Stover DG, Wesolowski R, Sardesai S, Noonan A, Reinbolt R, VanDeusen J, Williams N, Cherian MA, Li Z, Young G, Palettas M, Stephens J, Liu J, Luff A, Ramaswamy B, Lustberg M. Morgan E, et al. World J Surg Oncol. 2020 Jan 14;18(1):11. doi: 10.1186/s12957-019-1780-8. World J Surg Oncol. 2020. PMID: 31937323 Free PMC article.
Efficacy of different dosing schedules of capecitabine for metastatic breast cancer: a single-institution experience.
Suresh A, Ganju A, Morgan E, Palettas M, Stephens JA, Liu J, Berger M, Vargo C, Noonan A, Reinbolt R, Cherian M, VanDeusen J, Sardesai S, Wesolowski R, Stover DG, Lustberg M, Ramaswamy B, Williams N. Suresh A, et al. Invest New Drugs. 2020 Oct;38(5):1605-1611. doi: 10.1007/s10637-020-00891-9. Epub 2020 Jan 14. Invest New Drugs. 2020. PMID: 31938949
The impact of granulocyte colony-stimulating factor use in patients with metastatic breast cancer treated with palliative chemotherapy: a single-institution retrospective review.
Mousa L, Stephens JA, Berger M, Ramaswamy B, Lustberg M, Sardesai S, Williams N, VanDeusen J, Stover D, Cherian M, Morgan E, Wesolowski R. Mousa L, et al. Support Care Cancer. 2020 Nov;28(11):5537-5545. doi: 10.1007/s00520-020-05392-2. Epub 2020 Mar 17. Support Care Cancer. 2020. PMID: 32185556
Prospective Decision Analysis Study of Clinical Genomic Testing in Metastatic Breast Cancer: Impact on Outcomes and Patient Perceptions.
Stover DG, Reinbolt RE, Adams EJ, Asad S, Tolliver K, Abdel-Rasoul M, Timmers CD, Gillespie S, Chen JL, Ali SM, Collier KA, Cherian MA, Noonan AM, Sardesai S, VanDeusen J, Wesolowski R, Williams N, Lee CN, Shapiro CL, Macrae ER, Ramaswamy B, Lustberg MB. Stover DG, et al. JCO Precis Oncol. 2019 Nov 18;3:PO.19.00090. doi: 10.1200/PO.19.00090. eCollection 2019. JCO Precis Oncol. 2019. PMID: 32923860 Free PMC article.
48 results